Literature DB >> 1705829

Mutations of the p53 gene in lymphoid leukemia.

K Sugimoto1, H Toyoshima, R Sakai, K Miyagawa, K Hagiwara, H Hirai, F Ishikawa, F Takaku.   

Abstract

p53 is currently considered to be a tumor suppressor gene product, and its alterations are suggested to be involved in several human malignancies. Here we show evidence of the possible involvement of p53 gene mutations in lymphoid leukemias studied by reverse transcriptase-polymerase chain reaction, single strand conformation polymorphism analysis, and nucleotide sequencing. Fourteen patients with various leukemias were examined and two with acute lymphoblastic leukemia and one with Waldenström's macroglobulinemia were identified to have mutations in the coding region of the p53 gene. These mutations included point mutation, triplet deletion, and single nucleotide insertion. Furthermore, expression of the wild-type p53 mRNA was not detected in the samples from these three patients. In one of them, chromosome 17p was deleted, suggesting the absence of the nonmutated p53 gene, whereas in the other two patients, chromosome 17p seemed to be intact by cytogenetic analysis. Our results suggest that alterations of the p53 gene may have a role in the genesis of some leukemias.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705829

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Absence of hereditary p53 mutations in 10 familial leukemia pedigrees.

Authors:  C A Felix; D D'Amico; T Mitsudomi; M M Nau; F P Li; J F Fraumeni; D E Cole; J McCalla; G H Reaman; J Whang-Peng
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

2.  Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Moqin Qiu; Yingchun Liu; Xiangyuan Yu; Linyuan Qin; Chunhua Bei; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Songqing He; Hongping Yu
Journal:  Tumour Biol       Date:  2015-10-17

3.  Translational regulation of human p53 gene expression.

Authors:  L Fu; M D Minden; S Benchimol
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

4.  Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population.

Authors:  Mang Xiao; Lei Zhang; Xinhua Zhu; Jun Huang; Huifen Jiang; Sunhong Hu; Yuehui Liu
Journal:  BMC Cancer       Date:  2010-04-18       Impact factor: 4.430

5.  Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma.

Authors:  K Iyota; K Takeda; F Matsuzuka; T Okabayashi; S Morita; K Kuma; K Hashimoto
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

6.  MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Authors:  L Gu; N Zhu; H W Findley; M Zhou
Journal:  Leukemia       Date:  2008-02-14       Impact factor: 11.528

7.  An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms.

Authors:  T Tanaka; K Tanaka; S Ogawa; M Kurokawa; K Mitani; J Nishida; Y Shibata; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  1995-01-16       Impact factor: 11.598

8.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.